JP2009534418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534418A5 JP2009534418A5 JP2009506778A JP2009506778A JP2009534418A5 JP 2009534418 A5 JP2009534418 A5 JP 2009534418A5 JP 2009506778 A JP2009506778 A JP 2009506778A JP 2009506778 A JP2009506778 A JP 2009506778A JP 2009534418 A5 JP2009534418 A5 JP 2009534418A5
- Authority
- JP
- Japan
- Prior art keywords
- absent
- hydrogen
- alkyl
- membered ring
- hydroxyalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003277 amino group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- -1 chloro, fluoro, methyl Chemical group 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 claims 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79347106P | 2006-04-20 | 2006-04-20 | |
| US60/793,471 | 2006-04-20 | ||
| PCT/US2007/066985 WO2007124369A2 (en) | 2006-04-20 | 2007-04-19 | Method of inhibiting c kit kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534418A JP2009534418A (ja) | 2009-09-24 |
| JP2009534418A5 true JP2009534418A5 (enExample) | 2014-08-14 |
| JP5595727B2 JP5595727B2 (ja) | 2014-09-24 |
Family
ID=38625740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506778A Expired - Fee Related JP5595727B2 (ja) | 2006-04-20 | 2007-04-19 | Ｃ−ｋｉｔキナーゼ阻害法 |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP2397138B1 (enExample) |
| JP (1) | JP5595727B2 (enExample) |
| KR (1) | KR101448052B1 (enExample) |
| CN (2) | CN102670605B (enExample) |
| AU (1) | AU2007240400B2 (enExample) |
| BR (1) | BRPI0710542B8 (enExample) |
| CA (1) | CA2649755C (enExample) |
| CO (1) | CO6382175A2 (enExample) |
| CR (1) | CR10450A (enExample) |
| EA (1) | EA016611B1 (enExample) |
| EC (1) | ECSP088842A (enExample) |
| ES (2) | ES2389678T3 (enExample) |
| GT (1) | GT200800225A (enExample) |
| IL (1) | IL194846A (enExample) |
| MX (1) | MX2008013528A (enExample) |
| MY (1) | MY147226A (enExample) |
| NO (1) | NO342001B1 (enExample) |
| NZ (1) | NZ572200A (enExample) |
| SG (1) | SG171592A1 (enExample) |
| WO (1) | WO2007124369A2 (enExample) |
| ZA (1) | ZA200809874B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2840029C (en) | 2011-07-27 | 2021-07-20 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| CN104370880A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类蛋白酶抑制剂及其制备方法和用途 |
| US10259807B2 (en) | 2013-07-22 | 2019-04-16 | Idorsia Pharmaceuticals Ltd. | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
| EA032927B1 (ru) | 2015-01-15 | 2019-08-30 | Идорсия Фармасьютиклз Лтд | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| CN105753770A (zh) * | 2015-05-27 | 2016-07-13 | 上海佐林生物医药有限公司 | 蛋白激酶抑制剂制备方法、中间体、制备方法及应用 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2193143T3 (es) | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| ITMI992711A1 (it) * | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
| CN100491374C (zh) * | 2002-08-02 | 2009-05-27 | Ab科学公司 | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 |
| WO2005040139A2 (en) * | 2003-10-23 | 2005-05-06 | Ab Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
| GB0326601D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
| BRPI0507271A (pt) * | 2004-01-30 | 2007-06-26 | Ab Science | 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase |
| EP1807077B1 (en) * | 2004-10-22 | 2016-11-23 | Janssen Pharmaceutica NV | Inhibitors of c-fms kinase |
| US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| JP2009511628A (ja) * | 2005-10-18 | 2009-03-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｆｌｔ３キナーゼの阻害方法 |
| CN101466686A (zh) * | 2006-04-20 | 2009-06-24 | 詹森药业有限公司 | C-fms激酶抑制剂 |
| NZ572073A (en) * | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase |
| US8815867B2 (en) * | 2006-04-20 | 2014-08-26 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
-
2007
- 2007-04-19 EP EP11161399.8A patent/EP2397138B1/en active Active
- 2007-04-19 CA CA2649755A patent/CA2649755C/en active Active
- 2007-04-19 EP EP07760927A patent/EP2015748B1/en active Active
- 2007-04-19 KR KR1020087028216A patent/KR101448052B1/ko not_active Expired - Fee Related
- 2007-04-19 JP JP2009506778A patent/JP5595727B2/ja not_active Expired - Fee Related
- 2007-04-19 MX MX2008013528A patent/MX2008013528A/es active IP Right Grant
- 2007-04-19 ES ES07760927T patent/ES2389678T3/es active Active
- 2007-04-19 CN CN201210022810.8A patent/CN102670605B/zh not_active Expired - Fee Related
- 2007-04-19 EA EA200870454A patent/EA016611B1/ru unknown
- 2007-04-19 CN CN2007800231790A patent/CN101610768B/zh not_active Expired - Fee Related
- 2007-04-19 AU AU2007240400A patent/AU2007240400B2/en not_active Ceased
- 2007-04-19 ES ES11161399.8T patent/ES2458291T3/es active Active
- 2007-04-19 WO PCT/US2007/066985 patent/WO2007124369A2/en not_active Ceased
- 2007-04-19 BR BRPI0710542A patent/BRPI0710542B8/pt not_active IP Right Cessation
- 2007-04-19 NZ NZ572200A patent/NZ572200A/en not_active IP Right Cessation
- 2007-04-19 SG SG201102829-7A patent/SG171592A1/en unknown
-
2008
- 2008-10-20 MY MYPI20084185A patent/MY147226A/en unknown
- 2008-10-21 GT GT200800225A patent/GT200800225A/es unknown
- 2008-10-22 IL IL194846A patent/IL194846A/en active IP Right Grant
- 2008-10-22 EC EC2008008842A patent/ECSP088842A/es unknown
- 2008-10-24 CO CO08113911A patent/CO6382175A2/es active IP Right Grant
- 2008-11-19 ZA ZA2008/09874A patent/ZA200809874B/en unknown
- 2008-11-20 NO NO20084892A patent/NO342001B1/no not_active IP Right Cessation
- 2008-11-20 CR CR10450A patent/CR10450A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534418A5 (enExample) | ||
| KR20210087440A (ko) | 삼중 음성 유방암의 치료를 위한 병용 요법 | |
| CA2506308A1 (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
| JP2019517487A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| CN103269701A (zh) | 用于治疗野生型egfr和/或kras患者的非小细胞肺癌的hsp90抑制剂 | |
| JP7182304B2 (ja) | インドリノン化合物の使用 | |
| RU2727802C2 (ru) | Апилимод для применения в лечении рака почек | |
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| JP2011527703A (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| JP2009536620A5 (enExample) | ||
| JP2014525464A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| JP2015529194A5 (enExample) | ||
| CN108779073A (zh) | 用于治疗癌症的组合物和方法 | |
| CN111788207A (zh) | 二噁烷并喹啉类化合物及其制备方法与应用 | |
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2013511526A5 (enExample) | ||
| RU2015108755A (ru) | Комбинация ингибитора pik3 и ингибитора с-мет | |
| Malekan et al. | Vascular endothelial growth factor receptors [VEGFR] as target in breast cancer treatment: current status in preclinical and clinical studies and future directions | |
| JP2020531593A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| RU2007105233A (ru) | Производные порфирина и их применение в фотонно-активационной терапии | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 |